1Y Close · As of Aug 26, 2026
Daewoong Pharma operates in the Pharmaceuticals sector.
Legal name: DAEWOONG PHARMA
In fiscal year 2025, Daewoong Pharma (069620) reported revenue of 1.57 trillion KRW, up 10.4% from 1.42 trillion KRW a year earlier.
Operating profit was 196.8 billion KRW and net income was 192.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 1.48 trillion KRW, with a P/B of 1.31.
These figures can be verified in the DART filing (receipt no. 20260318001528).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 1.6T | 196.8B | 192.9B |
| 2024 | 1.4T | 147.9B | 23.3B |
| 2023 | 1.4T | 122.6B | 120.0B |
Recent Filings
Proxy Solicitation Reference
Meeting Notice
Officer/Major Shareholder Ownership Report
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-25 | Proxy Solicitation Reference |
| 2026-08-25 | Meeting Notice |
| 2026-08-21 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-07-29 | Operating (Preliminary) Earnings (Fair Disclosure) |